Opko Health Inc (OPK) Stock Price, Quote & News

Company Profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 305 575 4100

Website: www.opko.com

Address:

4400 Biscayne Boulevard, Miami, United States

Mike18181 Aug. 18 at 7:10 PM

$OPK The accounting. Is rigged to show a onetime gain. Its a Pooly managed company ridfled with LIES. There is zero growth since KRAPCO purchased BRL. Revenue shrinkscabd not grow. Cashflow now is -124 million for the quarter. Yes, a Shet Show. Sell Investment it smells like frost

0 · Reply

Dutan_Billionaire Aug. 18 at 4:16 PM

$OPK Started a new position here. I can see this moving up to $3.00

3 · Reply

Gasbagger Aug. 17 at 8:50 PM

$OPK must be setting up for anther Golden Cross . That is a reverse Golden Cross.

0 · Reply

Brasil07 Aug. 17 at 3:07 PM

$OPK this share show only the same loop, I really think that management don't want that the price go to 2 usd

2 · Reply

Gasbagger Aug. 17 at 3:08 AM

$OPK when will Opko pay the Israeli Gvt the 250 million they owe them for back taxes? Will they burn through all the cash and then file BK to escape the finding and to ditch all of its shareholders?

1 · Reply

tradertrash Aug. 16 at 8:46 PM

$OPK i wish they would sell it, but this big ol loser is just too lucrative for them to let go, failure pays extremely well, can't give that up

0 · Reply

Gasbagger Aug. 16 at 6:15 PM

$OPK is already cash flush. Why take on new debt and pay an extreme interest rate? Opko is Frosts personal piggy bank.

1 · Reply

tymtested Aug. 16 at 1:32 AM

$OPK I can’t believe analysts aren’t all over this. Opko has been trying to balance between R&D financing needs and the stock buyback program, just buying a few shares each quarter, then comes the surprise mazdutide royalties. They can see the stock price is about to go up thus creating the urgency to get $125M now. Now, they can accelerate the buyback program at lower stock prices and fund R&D pipe! BUYING OPPORTUNITY!

0 · Reply

tymtested Aug. 16 at 12:51 AM

$OPK maybe more stock buyback while stock is low?.?maybe accelerate buying on existing program since they have more cash.

0 · Reply

tymtested Aug. 16 at 12:48 AM

$OPK payments to healthcare royalties is capped ar $187.5 but will likely be much less. When incoming royalties exceed the interest payment, excess will be applied to the principle. This is all good… just tell us what your plans are for the money besides general corporate purposes.

0 · Reply

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

2026-08-03T11:25:21.000Z - 16 days ago

Cocrystal Pharma announces $5M investment from Opko Health

COCP

2026-08-03T11:15:31.000Z - 16 days ago

Cocrystal Pharma announces $5M private placement with Opko Health

COCP

2026-07-27T20:50:40.000Z - 22 days ago

Opko Health sees Q3 revenue $131M-$142M, consensus $134.65M

2026-07-27T20:50:27.000Z - 22 days ago

Opko Health sees FY26 revenue $560M-$585M, consensus $536.88M

2026-07-27T20:45:11.000Z - 22 days ago

Opko Health reports Q2 EPS (1c), one estimate (11c)

Jul 27, 2026, 4:30 PM EDT - 22 days ago

OPKO Health Earnings Call Transcript: Q2 2026

Jul 27, 2026, 4:30 PM EDT - 22 days ago

OPKO Health Earnings release: Q2 2026

Jul 27, 2026, 4:30 PM EDT - 22 days ago

OPKO Health Quarterly report: Q2 2026

Jul 27, 2026, 4:05 PM EDT - 22 days ago

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

Jul 23, 2026, 12:30 PM EDT - 26 days ago

OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026

Jun 18, 2026, 10:00 AM EDT - 2 months ago

OPKO Health Transcript: AGM 2026

2026-06-16T13:36:09.000Z - 2 months ago

Entera Bio and Opko Health present preclinical data for oral peptides

ENTX

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

Jun 3, 2026, 4:20 PM EDT - 2 months ago

OPKO Health Transcript: Jefferies Global Healthcare Conference 2026

May 15, 2026, 8:00 AM EDT - 3 months ago

OPKO Health Proxy statement: Proxy filing

May 12, 2026, 8:00 AM EDT - 3 months ago

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

May 8, 2026, 7:00 AM EDT - 3 months ago

OPKO Health Slides: Corporate presentation

Apr 30, 2026, 8:30 AM EDT - 3 months ago

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

Apr 30, 2026, 8:00 AM EDT - 3 months ago

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

Apr 30, 2026, 8:00 AM EDT - 3 months ago

OPKO Health Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

OPKO Health Proxy statement: Proxy filing

2026-04-29T12:37:59.000Z - 4 months ago

Opko Health downgraded to Market Perform from Outperform at Barrington

Apr 28, 2026, 4:30 PM EDT - 4 months ago

OPKO Health Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 4 months ago

OPKO Health Earnings release: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 4 months ago

OPKO Health Quarterly report: Q1 2026

Apr 28, 2026, 4:05 PM EDT - 4 months ago

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

Apr 22, 2026, 8:00 AM EDT - 4 months ago

OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Apr 21, 2026, 4:05 PM EDT - 4 months ago

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

2026-03-02T14:20:11.000Z - 6 months ago

Opko Health price target lowered to $1.50 from $2.25 at Barrington

Feb 27, 2026, 8:00 AM EST - 6 months ago

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

Feb 26, 2026, 4:30 PM EST - 6 months ago

OPKO Health Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

OPKO Health Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

OPKO Health Earnings release: Q4 2025

Feb 26, 2026, 4:05 PM EST - 6 months ago

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

Feb 12, 2026, 8:00 AM EST - 6 months ago

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

2026-02-04T13:16:35.000Z - 7 months ago

Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet

ENTX

Feb 4, 2026, 8:00 AM EST - 7 months ago

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

Jan 14, 2026, 4:30 PM EST - 7 months ago

OPKO Health Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:11 PM EST - 8 months ago

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 9 months ago

OPKO Health Slides: Corporate presentation

2025-11-20T09:50:09.000Z - 9 months ago

Opko Health initiated with a Neutral at JPMorgan

Nov 19, 2025, 4:05 PM EST - 9 months ago

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

2025-10-30T20:10:16.000Z - 10 months ago

Opko Health downgraded to Hold from Buy at Jefferies

2025-10-29T20:36:22.000Z - 10 months ago

Opko Health reports Q3 EPS 3c, consensus (5c)

Oct 29, 2025, 4:30 PM EDT - 10 months ago

OPKO Health Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

OPKO Health Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

OPKO Health Earnings release: Q3 2025

Oct 29, 2025, 4:05 PM EDT - 10 months ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

2025-10-29T12:10:25.000Z - 10 months ago

Opko Health’s ModeX enters license, collab agreement with Regeneron

REGN

2025-10-28T12:21:29.000Z - 10 months ago

Opko Health’s ModeX Therapeutics begins trial of MDX2004

Oct 22, 2025, 4:05 PM EDT - 10 months ago

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

2025-09-22T12:00:42.000Z - 11 months ago

Opko Health management to meet with Barrington

Sep 15, 2025, 8:30 AM EDT - 1 year ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Jul 31, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Quarterly report: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings release: Q2 2025

Jul 31, 2025, 4:05 PM EDT - 1 year ago

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

Jun 30, 2025, 8:01 AM EDT - 1 year ago

NextPlat Issues Interim CEO Update Shareholder Letter

NXPL

Jun 25, 2025, 11:00 AM EDT - 1 year ago

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

Jun 4, 2025, 11:05 AM EDT - 1 year ago

OPKO Health Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 9:00 AM EDT - 1 year ago

OPKO Health Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

OPKO Health to Participate in Two Upcoming Investor Conferences

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Quarterly report: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings release: Q1 2025

Apr 4, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Mar 17, 2025, 8:57 AM EDT - 1 year ago

OPKO and Entera partner to develop obesity pill

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q4 2024

Feb 27, 2025, 4:10 PM EST - 1 year ago

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

Jan 15, 2025, 6:00 PM EST - 1 year ago

OPKO Health Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

OPKO Health Slides: FY 2025

Jan 9, 2025, 11:45 AM EST - 1 year ago

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 1:30 PM EST - 1 year ago

OPKO Health Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024, 8:00 AM EST - 1 year ago

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

NXPL

Nov 14, 2024, 6:00 AM EST - 1 year ago

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

BABA NXPL

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q3 2024

Oct 7, 2024, 8:00 AM EDT - 2 years ago

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Oct 7, 2024, 8:00 AM EDT - 2 years ago

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

NXPL

Sep 16, 2024, 7:30 AM EDT - 2 years ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Aug 30, 2024, 8:00 AM EDT - 2 years ago

OPKO Health Proxy statement: Proxy Filing

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings release: Q2 2024

Aug 7, 2024, 4:06 PM EDT - 2 years ago

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

Jul 17, 2024, 4:14 PM EDT - 2 years ago

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

Jun 6, 2024, 10:30 AM EDT - 2 years ago

OPKO Health Transcript: Jefferies 2024 Global Healthcare Conference

May 31, 2024, 10:48 AM EDT - 2 years ago

OPKO Health to Participate in the Jefferies Global Healthcare Conference

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Quarterly report: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings release: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

May 3, 2024, 8:00 AM EDT - 2 years ago

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Mar 5, 2024, 8:52 AM EST - 2 years ago

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Feb 29, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Annual report: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings release: Q4 2023

Feb 27, 2024, 4:05 PM EST - 2 years ago

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Feb 22, 2024, 4:05 PM EST - 2 years ago

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Feb 16, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing

Jan 10, 2024, 6:45 PM EST - 2 years ago

OPKO Health Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 4:05 PM EST - 2 years ago

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

Jan 4, 2024, 11:31 PM EST - 2 years ago

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Jan 3, 2024, 5:05 PM EST - 2 years ago

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Nov 28, 2023, 7:00 AM EST - 2 years ago

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Nov 7, 2023, 6:45 AM EST - 3 years ago

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

SOPH

Nov 6, 2023, 4:30 PM EST - 3 years ago

OPKO Health Earnings Call Transcript: Q3 2023

Nov 6, 2023, 4:30 PM EST - 3 years ago

OPKO Health Quarterly report: Q3 2023

Nov 6, 2023, 4:30 PM EST - 3 years ago

OPKO Health Earnings release: Q3 2023

Nov 6, 2023, 4:05 PM EST - 3 years ago

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 2, 2023, 10:00 AM EDT - 3 years ago

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Oct 31, 2023, 8:00 AM EDT - 3 years ago

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Mike18181 Aug. 18 at 7:10 PM

0 · Reply

Dutan_Billionaire Aug. 18 at 4:16 PM

$OPK Started a new position here. I can see this moving up to $3.00

3 · Reply

Gasbagger Aug. 17 at 8:50 PM

$OPK must be setting up for anther Golden Cross . That is a reverse Golden Cross.

0 · Reply

Brasil07 Aug. 17 at 3:07 PM

$OPK this share show only the same loop, I really think that management don't want that the price go to 2 usd

2 · Reply

Gasbagger Aug. 17 at 3:08 AM

$OPK when will Opko pay the Israeli Gvt the 250 million they owe them for back taxes? Will they burn through all the cash and then file BK to escape the finding and to ditch all of its shareholders?

1 · Reply

tradertrash Aug. 16 at 8:46 PM

$OPK i wish they would sell it, but this big ol loser is just too lucrative for them to let go, failure pays extremely well, can't give that up

0 · Reply

Gasbagger Aug. 16 at 6:15 PM

$OPK is already cash flush. Why take on new debt and pay an extreme interest rate? Opko is Frosts personal piggy bank.

1 · Reply

tymtested Aug. 16 at 1:32 AM

0 · Reply

tymtested Aug. 16 at 12:51 AM

$OPK maybe more stock buyback while stock is low?.?maybe accelerate buying on existing program since they have more cash.

0 · Reply

tymtested Aug. 16 at 12:48 AM

0 · Reply

TommyCotton Aug. 15 at 9:49 PM

$OPK so we take the $125 million now instead of royalties over time. Interest fluctuates not under around 11%. Expensive money—but it doesn’t dilute by selling shares at a $1.50 or less. Maybe lessor of two evils. Big question what’s done with the money. If used to offset wasteful management its a BIG Loss. If it’s preparing to go further with trials based on positive data without diluting then maybe not so bad.

0 · Reply

Mike18181 Aug. 15 at 8:24 PM

$OPK Opko Cashflow /No budget is eating through Cash like " flesh eating paracites".. why do you think they keep borrowing. OpKo is Incompetent with Finance and *Mr. FORM 4 IS RUNNING THE SHOW.. IT A HORROR FLICK FOR ALL STAKEHOLDERS.. rated R for Retarded Mgmt. Cerebral and deficient motor skills.

0 · Reply

Mike18181 Aug. 15 at 7:41 PM

$OPK Frost is Metally ill, and is unfit..... " But fit to be an unfit CEO ".. buy out now about 1.20 ps. The Modex guys wish they never met frost. There investment is SHET,poop, dump, compost... twisted tirds..

0 · Reply

Gasbagger Aug. 15 at 4:41 PM

$OPK Who borrows and pays 62 Million in interest that is already flush in cash????? The Mazdutide Payments will be capped at $187.5 million, subject to certain indemnified liabilities and expenses. It doesn't smell right.

0 · Reply

tymtested Aug. 15 at 12:59 AM

$OPK mazdutide must have demonstrated significant sales growth quickly given it hasn’t been on the radar. No mention of it in recent ER. There is simply no way health royalties would have loaned $125M without credible sales numbers. Maybe Rayaldee will be well received in China.

0 · Reply

tymtested Aug. 15 at 12:02 AM

$OPK the way the deal is structured Opko will payoff the $125 as soon as possible based on growth of royalties from Ngenla and mazdutide. Mazdutide is expected to grow very fast up to $1B sales in just a couple of years.

0 · Reply

tymtested Aug. 14 at 11:56 PM

$OPK I wonder what opko has cooking that makes them need an additional $125M at this particular point in time.

0 · Reply

magadog Aug. 14 at 3:30 PM

$OPK The dumbest Arrogant mental case CEO on the planet but any long term shareholders like me are even more stupid nobody in the M&A world is interestd in this box of rocks please someone stop the misery

1 · Reply

tradertrash Aug. 14 at 3:15 PM

$OPK dilution pollution... spin it anyway u like... it's a stonk killer imo

0 · Reply

Zerrat Aug. 14 at 3:00 PM

$OPK pump is done then lower lows

0 · Reply

Zerrat Aug. 14 at 2:58 PM

$OPK lol

0 · Reply

Brasil07 Aug. 14 at 1:56 PM

$OPK no Mercy for shareholders if Frost and his board stay on, for us Is the end of every hope

0 · Reply

Market Cap	1.02B
Revenue (ttm)	606.88M
Net Income (ttm)	-225.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-37.19%
Debt to Equity Ratio	0.22

Volume	1,602,000
Avg Vol	3,623,066
Day's Range	N/A - N/A
Shares Out	746.33M
Stochastic %K	38%
Beta	1.51
Analysts	Sell
Price Target	$2.56